# US 2026/0263585 A1 · Universal influenza mrna vaccine and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263585 A1
- Document ID: US20260263585A1
- Status: Published application
- Kind: A1
- Application number: 19/166,221
- Filed: 2024-03-18
- Published: 2026-09-10
- Earliest claimed: 2023-03-17
- Assignees: Shanghai Institute of Biological Products Co., Ltd.
- Applicants: Shanghai Institute of Biological Products Co., Ltd.
- Inventors: Jian LUO; Feifei XIONG; Baoyuan SHANG; Mei ZHENG; Xiuling LI
- Web page: https://patentgrep.com/patent/US20260263585A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C07K 14/005: from viruses
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/11: Orthomyxoviridae, e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/625: {containing a sequence coding for a signal sequence}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A universal influenza mRNA vaccine is used to encode a protein. The resulting protein encoded by the universal influenza mRNA vaccine has a matrix protein 2 extracellular domain (M2e), a hemagglutinin (HA) stem LAH region and a nucleoprotein (NP) of an influenza A virus. The universal influenza mRNA vaccine is used in a mouse animal model. The universal influenza mRNA vaccine can induce strong humoral immune and cellular immune responses, and can protect animal model mice against various influenza A viruses.

## Claims

### Claim 1

A recombinant protein wih a structure represented by the following formula (I) or (II) from the N-terminus to the C-terminus:
wherein,
each “-” is independently a bond or a linking peptide;
S is absent or a signal peptide;
M is absent, or n tandem influenza virus matrix protein 2 extracellular domains (M2e) or immunogenic fragments thereof;
H is absent, or m tandem hemagglutinin (HA) stem (LAH) regions or immunogenic fragments thereof;
N is nucleoprotein (NP) or an immunogenic fragment thereof;
wherein n is an integer from 1 to 6, and m is an integer from 1 to 6; and
M and H are not absent simultaneously.

### Claim 2 (depends on 1)

The recombinant protein of claim 1, wherein the nucleoprotein (NP) is generated by amino acid mutations in one or more nuclear localization signal regions of the NP protein from wild-type PR8 strain, and the nuclear localization signal region comprises amino acid positions 2-12, 197-215, 339-344 of SEQ ID NO: 10, or a combination thereof.

### Claim 3 (depends on 2)

The recombinant protein of claim 2, wherein the mutation is located at the amino acid positions corresponding to positions 6, 7, 212, 213, 214, 215, 341, 342 of SEQ ID NO: 10, or a combination thereof.

### Claim 4 (depends on 1)

The recombinant protein of claim 1, wherein the amino acid sequence of the nucleoprotein is selected from the group consisting of:
(N1) the amino acid sequence of SEQ ID NO: 10;
(N2) an amino acid sequence obtained by substituting, deleting, altering, or inserting one or more amino acid residues in the sequence of SEQ ID NO: 10, or adding 1 to 30 amino acid residues (preferably 1-10 amino acid residues, more preferably 1-5 amino acid residues) at its N-terminus or C-terminus; the obtained amino acid sequence has ≥85% (preferably 90%, more preferably 95%, such as ≥96%, ≥97%, ≥98% or ≥99%) sequence identity with the sequence of SEQ ID NO: 10; and the obtained amino acid sequence exhibits equivalent or similar immunogenicity to the sequence in (N1) and does not undergo nuclear localization.

### Claim 5 (depends on 1)

The recombinant protein of claim 1, wherein the M has a structure represented by the following formula (III) from the N-terminus to the C-terminus:
wherein,
each “-” is independently a bond or a linking peptide;
M1, M2, M3, and M4 are each independently absent or M2e or an immunogenic fragment thereof, and M1, M2, M3, and M4 are not absent simultaneously.

### Claim 6 (depends on 5)

The recombinant protein of claim 5, wherein the amino acid sequences of M1, M2, M3, and M4 are each independently selected from the group consisting of: SEQ ID NO: 3, 4, 5, and 6.

### Claim 7 (depends on 5)

The recombinant protein of claim 5, wherein the amino acid sequence of M is shown in SEQ ID NO: 12, or has ≥85% (preferably ≥90%, more preferably ≥95%, e.g., ≥96%, ≥97%, ≥98%, or ≥99%) sequence identity to SEQ ID NO: 12, and exhibits equivalent or similar immunogenicity as SEQ ID NO: 12.

### Claim 8 (depends on 1)

The recombinant protein of claim 1, wherein the H has a structure represented by the following formula (IV) from the N-terminus to the C-terminus:
wherein,
each “-” is independently a bond or a linking peptide;
H1, H2, and H3 are each independently absent or represent a hemagglutinin stem LAH region or an immunogenic fragment thereof, and H1, H2, and H3 are not absent simultaneously.

### Claim 9 (depends on 8)

The recombinant protein of claim 8, wherein the amino acid sequences of H1, H2, and H3 are each independently selected from the group consisting of: SEQ ID NO: 7, 8, and 9.

### Claim 10 (depends on 8)

The recombinant protein of claim 8, wherein the amino acid sequence of H is shown in SEQ ID NO: 13, or has ≥85% (preferably 90%, more preferably ≥95%, e.g., ≥96%, ≥97%, ≥98%, or ≥99%) sequence identity to SEQ ID NO: 13, and exhibits equivalent or similar immunogenicity as SEQ ID NO: 13.

### Claim 11 (depends on 1)

The recombinant protein of claim 1, wherein the recombinant protein comprises the amino acid sequence as set forth in SEQ ID NO: 1; or an amino acid sequence having ≥85% (preferably ≥90%, more preferably ≥95%, e.g., ≥96%, ≥97%, ≥98%, or ≥99%) sequence identity to SEQ ID NO: 1 and exhibiting equivalent or similar immunogenicity as SEQ ID NO: 1.

### Claim 12 (depends on 1)

A polynucleotide encoding the recombinant protein of claim 1.

### Claim 13 (depends on 12)

The polynucleotide of claim 12, wherein the polynucleotide is an mRNA having the nucleotide sequence of SEQ ID NO: 2.

### Claim 14 (depends on 12)

An mRNA vaccine composition, which comprises:
(i) the polynucleotide of claim 12, wherein the polynucleotide is mRNA;
(ii) a vaccinologically acceptable carrier.

### Claim 15 (depends on 14)

The vaccine composition of claim 14, wherein the vaccinologically acceptable carrier is a lipid nanoparticle.
